Enanta Pharmaceuticals Stock Current Valuation
| ENTA Stock | USD 8.60 0.23 2.60% |
Valuation analysis of Enanta Pharmaceuticals helps investors to measure Enanta Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Enanta Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Enanta Pharmaceuticals is based on 3 months time horizon. Increasing Enanta Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enanta Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enanta Stock. However, Enanta Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.6 | Real 7.22 | Hype 8.6 | Naive 9.19 |
The real value of Enanta Stock, also known as its intrinsic value, is the underlying worth of Enanta Pharmaceuticals Company, which is reflected in its stock price. It is based on Enanta Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Enanta Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Enanta Pharmaceuticals helps investors to forecast how Enanta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enanta Pharmaceuticals more accurately as focusing exclusively on Enanta Pharmaceuticals' fundamentals will not take into account other important factors: Enanta Pharmaceuticals Company Current Valuation Analysis
Enanta Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Enanta Pharmaceuticals Current Valuation | (10.45 M) |
Most of Enanta Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enanta Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Enanta Pharmaceuticals has a Current Valuation of (10.45 Million). This is 100.07% lower than that of the Biotechnology sector and 100.22% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.06% higher than that of the company.
Enanta Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enanta Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics of similar companies.Enanta Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Enanta Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.60) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | (10.45 M) | ||||
| Shares Outstanding | 21.19 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 94.00 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 2.53 X | ||||
| Revenue | 67.64 M | ||||
| Gross Profit | 86.16 M | ||||
| EBITDA | (121.69 M) | ||||
| Net Income | (116.05 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 55.47 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 7.03 X | ||||
| Cash Flow From Operations | (78.76 M) | ||||
| Short Ratio | 20.91 X | ||||
| Earnings Per Share | (5.48) X | ||||
| Target Price | 18.13 | ||||
| Number Of Employees | 145 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 182.27 M | ||||
| Total Asset | 376.65 M | ||||
| Retained Earnings | (323.04 M) | ||||
| Working Capital | 360 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 376.65 M |
About Enanta Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enanta Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Enanta Pharmaceuticals Piotroski F Score and Enanta Pharmaceuticals Altman Z Score analysis. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.